📰 BloombergBloombergCodex · 实盘不做把握 8/10
北京时间·🕒 发布 08-03 18:24:23时区推断·⟳ 抓取 08-03 18:54:56·⚡ 决策 08-04 02:50:33 +7h55m·84.5 天前
药明康德称被列入五角大楼清单损害声誉但上调全年收入指引
公司称1260H清单 designation 对声誉和美国业务关系造成不确定性，但上半年美国客户收入仍增长62%。
📄 原文Bloomberg↗ 原文
WuXi AppTec Co Ltd said its inclusion on the Pentagon’s list of companies allegedly tied to the Chinese military is dam…
不做 药明康德（02359.HK）
同一半年报/上调指引/1260H清单叙事已在近9小时内多次处理，当前Bloomberg稿为重复扩散；不再推卡。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 high · price-in 风险 high ↗
关键理由
- 公司称1260H清单 designation 对声誉和美国业务关系造成不确定性，但上半年美国客户收入仍增长62%。
- 公司同时将全年收入指引上调至585亿元至605亿元，核心正面业绩和指引催化已在近9小时内多次被系统处理。
主要风险
- 五角大楼清单相关诉讼和声誉影响是存量监管风险，当前稿件未给出新增禁令、客户流失或正式业务中断。
工具调用 · 历史记录,结果未知(1 种)
- search_processed_events · 结果未知
原文全文
展开原文 · 1,779 字
WuXi AppTec Co Ltd said its inclusion on the Pentagon’s list of companies allegedly tied to the Chinese military is damaging its reputation and injecting uncertainty into its critical US business, as it continues to challenge the designation.
The Defense Department named the major pharmaceutical contractor to the 1260H list in June, labeling it a company associated with the Chinese military. WuXi has since sued the Pentagon, seeking to void the designation and remove its name from the list.
“While our operations are fully functional as usual and we remain fully committed to serve our customers, the 1260H designation has defamed the company’s hard-won reputation and created severe market interference,” the company wrote in its half-yearly earnings report. “It has also created uncertainty over US business relationships and may eventually cause harm to the patients that rely on our scientific endeavors.”
The company said it has also filed a motion for preliminary injunction. A hearing has been held, but no ruling has been issued, according to WuXi. It is pursuing “all available legal remedies,” the company added.
Read More: Pentagon Names WuXi AppTec on Chinese Military List
The firm — which provides contract research, development and manufacturing services to drugmakers worldwide — earned 77% of its revenue from US customers in the first half of 2026. Revenue for the first six months exceeded analyst estimates, prompting WuXi to raise its full-year revenue guidance to 58.5 billion yuan to 60.5 billion yuan ($8.7 billion to $9 billion), up from 51.3 billion yuan to 53.0 billion yuan.
Revenue from US customers grew 62% in the period, suggesting US customers “remain unfazed” by the list inclusion, Bloomberg Intelligence analyst Jamie Maarten wrote.
The Defense Department named the major pharmaceutical contractor to the 1260H list in June, labeling it a company associated with the Chinese military. WuXi has since sued the Pentagon, seeking to void the designation and remove its name from the list.
“While our operations are fully functional as usual and we remain fully committed to serve our customers, the 1260H designation has defamed the company’s hard-won reputation and created severe market interference,” the company wrote in its half-yearly earnings report. “It has also created uncertainty over US business relationships and may eventually cause harm to the patients that rely on our scientific endeavors.”
The company said it has also filed a motion for preliminary injunction. A hearing has been held, but no ruling has been issued, according to WuXi. It is pursuing “all available legal remedies,” the company added.
Read More: Pentagon Names WuXi AppTec on Chinese Military List
The firm — which provides contract research, development and manufacturing services to drugmakers worldwide — earned 77% of its revenue from US customers in the first half of 2026. Revenue for the first six months exceeded analyst estimates, prompting WuXi to raise its full-year revenue guidance to 58.5 billion yuan to 60.5 billion yuan ($8.7 billion to $9 billion), up from 51.3 billion yuan to 53.0 billion yuan.
Revenue from US customers grew 62% in the period, suggesting US customers “remain unfazed” by the list inclusion, Bloomberg Intelligence analyst Jamie Maarten wrote.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。